Tumor cell migration is a fundamental process of metastasis. Pertussis toxine inhibits lysophosphatidic acid related cell migration by ADP-ribosylation of G proteins. We examined the in¯uence of pertussis toxine (PTX) on progression and metastasis of the human hormone-insensitive prostate cancer cell line PC-3 after orthotopic implantation in nude mice.
Introduction
Prostate cancer in one in two men is the most frequent tumor in Western society and the second cause of cancer death. 1 Already 25±40% of the patients present with systemic disease at the time of diagnosis. The majority of patients initially respond to endocrine therapy, however, escape from androgen ablation with progression to androgen independence inevitably occurs after a median of 2 y. 2 Due to the low proliferation rate of prostate cancer chemotherapy is ineffective which is re¯ected in the low response rates exceeding merely 30%. It has become evident that the progression of prostate cancer to metastatic hormone-resistant disease is a multistep process involving androgen receptor mutation, alterations of oncogenes and tumor suppressor genes, paracrine and autocrine growth factors and angiogenesis, cellular adhesion molecules and motility factors. 3±8 The limited therapeutic possibilities in hormone-resistant disease warrant the development of new treatment strategies. A ®rst step towards more promising approaches could be a better understanding of the metastatic process. Migration of tumor cells is a fundamental process of metastasis. Tumor cells migrate from the local tumor site into the circulatory system to invade adjacent organs and form distant metastases. In previous studies the signal transduction pathway for motility factors was characterized in vitro and it was demonstrated that pertussis toxine (PTX) potently inhibited lysophosphatidic acid-(LPA) induced cell motility.
9±11 However, detailed in vivo studies depend on clinically relevant animal models for metastic prostate cancer. We have recently shown that orthotopic implantation of human prostate cancer cell lines PC-3, PC-3-125-1L, TSU-Pr1 and LNCaP-FGC in athymic nude mice is a valid experimental model that reproducibly leads to local tumor growth and metastasis to locoregional lymphnodes and lungs. 12 In this present study we examined the in¯uence of pertussis toxine as potential antimotility factor on progression and metastasis of the human hormone-insensitive prostate cancer cell line PC-3 after orthotopic implantation into the dorsal prostate of athymic nude mice.
Materials and methods

Cell line and culture
The hormone-insensitive human prostate cancer cell line PC-3 was used in this study. The PC-3 cell line, established by Kaighn et al 13 from a human bone metastasis, was obtained from American Type Culture Collection (Rockville, MD, USA).
The PC-3 cell line was cultured as monolayer in tissue culture¯asks (Greiner Labortechnik, Germany) in Minimal Essential Medium (Seromed, Germany) 10% fetal calf serum (FCS). The media were supplemented with glutamine and penicillinastreptomycin. Cell cultures were maintained at 37 C in a humidi®ed incubator in an atmosphere of 5% CO 2 in air. At near con¯uence cells were washed with phosphate buffered saline (PBS), harvested with trypsinaEDTA solution and ®nally suspended in CA and Mg free balanced salt solution. Only single-cell suspensions of b 90% viability (Trypan blue exclusion) were used.
Animals
Athymic male nude mice (NMRI nuanu, 8±9 weeks old, from the breeding colony at the University of Essen Experimental Animal Center, Essen, Germany) were kept in groups of three in a laminar-¯ow cage under controlled environmental conditions (21±22 C, humidity 50% and 12 h lighting cycle). Sterilized food (obtained from Eckersmann, Rinteln, Germany) and acidi®ed drinking water were supplied ad libitum.
Tumor cell injection
Orthotopic implantation was carried out according to Rembrink et al. 12 After anesthesia with tribromoethanol a midline incision was made in the lower abdomen. A suspension of 5 6 10 5 PC-3 cells in 20 ml PBS was injected into the dorsal mouse prostate using a 20-gauge needle and a 50 ml glass syringe (Hamilton Bonaduz AG, Switzerland). This concentration was appropriate to reproducibly cause local tumor growth and locoregional lymphnode metastases in 100% within 40 d after implantation. 12 Beyond 40 d advanced local tumor growth lead to postrenal failure. Elevation of the thin capsule of the dorsal prostate indicated subcapsular deposition of the suspension. The abdomen was closed with single-stitch sutures and the mouse was ear-marked. To assess the normal weight of prostate and seminal vesicles of 8±9 weeks old nude mice no orthotopic implantation was performed in ®ve mice and the animals were left untreated.
Dose and application of pertussis toxine (PTX)
The mice received a concentration of 0.5 mg PTXa100 g body weight suspended in 0.3 ml NaCl given intraperitoneally at an interval of 4 d without anesthesia or additional medication. PTX was provided by Takeda Pharma, Germany. Treatment was begun 7 d after orthotopic implantation and since most animals were expected to die of obstructive uropathy beyond 40 days due to local tumor growth following orthotopic implantation of 5 6 10 5 PC-3 12 the PTX group received six injections of PTX and the experiment was limited to 37 d. The control group received six intraperitoneal injections of 0.3 ml phosphate buffered saline at an interval of 4 d.
Autopsy and histology
The mice were killed by cervical dislodgement at 37 d after tumor cell injection. After inspection of macroscopical tumor growth the prostate and seminal vesicles were taken out as one unit and the weight of the resected unit was assessed in milligramms (mg). Iliac and preaortic lymphnodes as well as the lungs were sampled. The transversal diameter of the largest lymphnode was measured in mm. The specimens were ®xed in 3.7% formalin, embedded in paraf®n, serially sectioned and stained with hematoxylin and eosin and examined at 100 and 400 power ®eld (light microscopy). Special attention was given to the morphological appearance of metastases and possible PTX related histological ®ndings. Red and white blood cell counts were taken at autopsy to test for hematological side effects of PTX.
Statistical analysis
To assess whether the reduction of local tumor weight due to PTX is signi®cant we used the two-sided Wilcoxon±Mann±Whitney-U-test. Fisher's exact test was used to assess the correlation between PTX treatment and lymphnode metastases as compared to the control.
Results
In the control group tumorigenicty was 100% (15 out of 15). Mean weight of the tumor bearing unit of prostate and seminal vesicles was 541 mg (range 243±763 mg). The rate of lymphnode metastases was 100% with a mean transversal diameter of 3.9 mm (range 1.2±5.4 mm). In the PTX group local take rate was 100% with a mean weight of 251 mg (range 88±478 mg) for the tumor bearing unit of Prostate cancer and pertussis toxine A Bex et al prostate and seminal vesicles (P two sided`0.0001). In contrast to the control group only 9 out of 15 mice (60%, P 0.017) developed lymphnode metastases to the iliac and preaortal lymphnodes. The mean transversal diameter of the lymphnodes was 2.3 mm (range 1.0± 4.5 mm). The results are summarized in Tables 1 and 2 . The mean weight of the normal unit of prostate and seminal vesicles in nude mice without orthotopic implantation was 62 mg (range 58±64 mg).
Histopathologically no difference could be disclosed in local tumors and lymphnode metastases of the control group and treatment group regarding a possible effect of PTX on morphological appearance at light microscopy. Figures 1 and 2 show local tumor and metastatic spread to a locoregional lymphnode of an animal treated with PTX. Microscopic tumor cell clusters were found equally in the lungs of all mice of the treatment as well as the control group. Moderate weight loss occured in the treatment group as compared to the control (Tables 1 and 2) . No hematologic side effects were disclosed after application of PTX.
Discussion
Cell migration is a vital process for the life of multicellular beings and is involved in a wide variety of physiological and pathological processes such as wound healing, angiogenesis and in¯ammatory reactions. 14 In metastasis malignant cells disaggregate and migrate from the local tumor site through lymphatic and blood vessels into adjacent and distant organs. Disaggregation of tumor cells is initiated by loss of epithelial cell adhesion molecules and cell migration is caused by motility factors which interact with speci®c cell surface receptors. 15 We recently demonstrated that cell motility and migration of human transitional carcinoma cells is potently stimulated by G protein coupled receptors correlated to calcium mobilization. 10 The In contrast the thrombin-induced cell motility of J 82 cells was not affected by PTX-treatment. 10 In 1986 Stryer and Bourne 9 described that PTX irreversibly inactivates certain G proteins and early studies demonstrated the inhibition of lymphoma invasion and liver metastasis formation by PTX without affecting cell proliferation. 16 The effect of PTX is dose-and timedependent. Already as low a concentration as 0.1 ngaml PTX completely inhibited LPA induced cell motility of the J 82 cell line as measured in the Boyden Chamber assay. Those in-vitro ®ndings prompted us to examine the effect of PTX on further human cancer cell lines in the Boyden Chamber assay. We disclosed similar inhibition of the migratory response to LPA by PTX in human cell lines of renal cell cancer, pancreatic carcinoma, breast cancer, melanoma, osteosarcoma and prostatic carcinoma, particularly the hormone-independent PC-3 cell line (data not shown). In an animal model of chemically induced bladder cancer in mice PTX caused signi®cantly less locally advanced tumors. 17 The mice were treated with different doses of PTX of which 0.5 mg PTXa100 g body weight proved to be the most effective treatment schedule. At this dose no side effects were observed. From these data we conclude that LPA related cell motility is a common process in cancer cells and that it is potentially inhibited by PTX-treatment.
In a ®rst clinical trial we disclosed that the application of PTX as antimotility factor in combination with an altered chemotherapy regimen caused objective response in previous chemotherapy refractory metastatic transitional-cell carcinoma. 18 Two out of 18 patients revealed complete remissions where two patients showed partial response. The onset of progressive disease upon withdrawal of the antimotility factor has led to the notion that the effect of this treatment modality is limited in time when used as intermittend therapy indicating that rather a continuous treatment should be applied.
These ®ndings from in-vitro and in-vivo studies as well as clinical trials regarding transitional cell carcinoma have encouraged us to investigate the antimotility effect of PTX in an in-vivo model of human hormone-resistant prostate cancer. The limited therapeutic possibilities in hormoneresistant disease warrant the development of new treatment strategies. In our study we used the model of orthotopic implantation of human prostate cancer cell lines into the dorsal prostate of athymic nude mice. 12 In contrast to other techniques such as subcutaneous, intravenous or intraperitoneal injections of human prostate cancer cell lines into nude mice with metastasis being a rare event 19 orthotopic tumor implantation of 1 6 10 6 cells of the TSU-Pr1, PC-3 and DU 145 cell lines reproducibly leads to local tumorigenicity of 100%Ðexcept for LNCaPÐand locoregional as well as distant metastases in up to 100% depending on the cell line and the time elapsed since orthotopic implantation. 12, 20 Particularly, the orthotopic implantation of 5 6 10 5 PC-3 cells causes local tumor growth and locoregional lymphnode metastases in 100% within 40 d. Since beyond 40 d most animals will eventually die from postrenal failure due to local tumor growth we killed the mice after 37 d. The PC-3 cell line was established from a bone metastasis from a patient with hormone-resistant prostate cancer and apart from being PSA-negative does not show any sensitivity to androgens. 13 Therefore, orthotopic implantation of the PC-3 cell line is an ideal and reliable in-vivo model to study the progression and metastasis of hormoneresistant disease and the effect of new treatment strategies. We did not perform orchiectomy since growth and metastasis of PC-3 in nude mice is not affected by castration. 21 The application of PTX signi®cantly reduced local tumor growth and locoregional lymphnode metastases after orthotopic implantation of PC-3 cells. We chose a concentration of 0.5 mg PTXa100 g body weight based on the animal experiment of chemically induced transitional cell cancer in mice. 17 In the Boyden Chamber assay pretreatment of PC-3 cells with 10 ngaml PTX for 24 h inhibited the cell motility induced by LPA (20 mM) (data not shown). Interestingly, it was shown in a recent study by Chen et al 22 that PTX had no effect on the LPA stimulated proliferation of PC-3 cells. The authors concluded from these data that LPA stimulates proliferation of PC-3 cells via G i -independent pathways. In an earlier study, Roos and van de Pavert 16 found reduced invasion of malignant lymphoma cells in hepatocyte cultures in vitro to 20% of control values after pretreatment with 0.5 gaml PTX for 4 h whereas proliferation was not affected. The inhibition of invasion persisted for 5 d despite a more than 100-fold increase in cell number. Therefore, there is evidence that LPA related migration and proliferation may not follow the same signal transduction pathways. In both groups microscopic metastases to the lungs were found, which is a consistent ®nding after orthotopic implantation of PC-3 cells. 12 The scattered and microscopic nature of these metastatic tumor cell clusters did not allow their quantitation by serial section and comparison of both groups. Apart from moderate weight loss no adverse effects were observed. There was no evidence of histological changes in the local tumor and the lymphnode metastases after exposure to PTX. Since all mice were killed at 37 d it remains unsolved whether the reduced progression and metastasis we observed after intraperitoneal injection of PTX is limited in time nor is it clear how the tumor behaves upon withdrawal of PTX. The fact, however, that the local tumor take rate was 100% in both groups and that lymphnode metastases did occur in the PTX group albeit reduced in size indicates that PTX rather delays than prevents progression and metastasis. Since there are limited therapeutic options once hormoneinsensitive prostate cancer has developed, the ®ndings support a possible role of PTX as an antimotility factor in the treatment of advanced and particularly hormoneresistant prostate cancer in a clinical trial.
Conclusions
The application of pertussis toxine after orthotopic implantation of the human, hormone-insensitive prostate cancer cell line PC-3 into the dorsal prostate of athymic nude mice leads to signi®cant reduction of local tumor growth and locoregional lymphnode metastases as compared to the control in the period of time observed. We therefore conclude that PTX acts as an antimotility factor which delays rather than prevents progression and metastasis and may have a possible role in the treatment of hormone-resistant prostate cancer.
